

Protalix BioTherapeutics, Inc.  
Form 8-K  
November 27, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): November 27, 2017**

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**



..

**Item 8.01. Other Events**

On November 27, 2017, the Company issued a press release announcing that positive results from the Company's Phase I/II open label extension trial of pegunigalsidase alfa, or PRX-102, were presented by Prof. Raphael Schiffmann, Director, Institute of Metabolic Disease at the Baylor Research Institute, Dallas, Texas, at the New Horizons in Fabry Disease Conference. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated November 27, 2017.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 27, 2017 **PROTALIX BIOTHERAPEUTICS, INC.**

By: /s/ Moshe Manor  
Name: Moshe Manor  
Title: President and Chief Executive Officer